Rheos Medicines is pioneering immunometabolism to tune metabolic pathways in immune cells and develop precision medicines for immune-mediated diseases. The company has built an integrated product engine that combines DNA sequencing, transcriptional and metabolomic profiling, and primary patient samples to identify drug targets and biomarkers. Central to the platform is a proprietary Immune Cell Encyclopedia (ICE) mapping metabolic pathways across immune cell types. Rheos’s initial pipeline focuses on therapeutics targeting CD4 and CD8 T cell subtypes with indications including inflammatory bowel disease, psoriasis, vitiligo and immuno-oncology applications. The company emphasizes addressing patient heterogeneity by pairing target discovery with biomarkers to enable precision treatment. Rheos was founded by Third Rock Ventures and is located in Cambridge, Massachusetts.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2018